Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial - Kaseb, A; Hasanov, E; Cao, H (Lancet Gastroenterol Hepatol, 2022)
et al.